基于RhoA/ROCK信号通路探讨复方斑蝥胶囊联合SOX化疗方案对胃癌患者的干预作用  

Intervention effect of compound cantharis capsule combined with SOX chemotherapy regimen on patients with gastric cancer based on RhoA/ROCK signaling pathway

作　　者：武红艳 贡艳 WU Hongyan;GONG Yan(Department of the Pharmacy,Yangzhou Hospital of Traditional Chinese Medicine,Yangzhou 225000,China;不详)

机构地区：[1]扬州市中医院药房,江苏扬州225000 [2]扬州市邗江妇幼保健院药剂科,江苏扬州225000

出　　处：《中国处方药》2025年第6期79-83,共5页Journal of China Prescription Drug

摘　　要：目的基于Ras同源基因家族成员A(RhoA)/Rho激酶(ROCK)信号通路探讨复方斑蝥胶囊联合SOX化疗方案(奥沙利铂+替吉奥)对胃癌患者的干预作用。方法选取2021年6月~2023年6月于扬州市中医院接受治疗的80例胃癌患者,按照随机数表法分为化疗组和联合组,各40例。化疗组接受SOX化疗方案治疗,联合组接受复方斑蝥胶囊联合SOX化疗方案治疗。以实体瘤疗效评定标准(RECIST)评价两组临床疗效。比较两组临床疗效、两组治疗前后血清肿瘤标志物[癌胚抗原(CEA)、癌抗原125(CA125)、糖类抗原19-9(CA19-9)],RhoA/ROCK信号通路相关因子表达(RhoA、ROCKⅠ、ROCKⅡ)、免疫功能[T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))]以及随访生存情况。结果联合组疾病总控制率(DCR)、客观控制率(ORR)分别为85.00%、37.50%,化疗组DCR、ORR分别为72.50%、42.50%,组间比较差异均无统计学意义(P>0.05)。治疗后,两组CEA、CA125、CA19-9、RhoA、ROCKⅠ、ROCKⅡ蛋白表达均降低(P<0.05),且联合组低于化疗组(P<0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均升高(P<0.05),且联合组高于化疗组(P<0.05);联合组随访18个月存活率高于化疗组(Log-rankχ^(2)=4.116,P=0.042)。结论复方斑蝥胶囊联合SOX化疗方案治疗胃癌效果确切,可抑制RhoA/ROCK信号通路相关因子表达,降低血清肿瘤标志物水平,改善免疫功能,延长患者的无病生存时间。Objective To explore the intervention effects of compound cantharis capsule combined with SOX chemotherapy regimen(oxaliplatin+tegafur)on patients with gastric cancer based on the Ras homologous gene family member A(RhoA)/Rho associated coiledcoil containing protein kinase(ROCK)signaling pathway.Methods A total of 80 patients with gastric cancer in Yangzhou Hospital of Traditional Chinese Medicine were selected from June 2021 to June 2023.They were randomly divided into the chemotherapy group and the combined group according to the random number table method,with 40 cases in each group.The chemotherapy group received SOX chemotherapy regimen,while the combined group were given compound cantharis capsule combined with SOX chemotherapy regimen.The clinical efficacy of the two groups was evaluated by response evaluation criteria in solid tumors(RECIST).The clinical efficacy,serum tumor markers[carcinoembryonic antigen(CEA),cancer antigen 125(CA125),carbohydrate antigen 19-9(CA19-9)],expressions of RhoA/ROCK signaling pathway-related proteins(RhoA,ROCKI,ROCKII),immune function[T lymphocyte subsets(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))],and follow-up survival status were compared between groups.Results The disease control rate(DCR)and objective response rate(ORR)in the combined group were 85.00%and 37.50%respectively,while those in the chemotherapy group were 72.50%and 42.50%respectively,without statistical differences(P>0.05).After treatment,the levels of CEA,CA125,CA19-9 and the protein expressions of RhoA,ROCKⅠand ROCKⅡin both groups were decreased(P<0.05),and the levels in the combined group were lower than those in the chemotherapy group(P<0.05).The levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were increased in both groups after treatment(P<0.05),and the above indicators were higher in the combined group than those in the chemotherapy group(P<0.05).The 18-month follow-up survival rate in combined group was higher than that in chemotherapy group(Log-rankχ^(2)=4.116,P=0.042).Conclusion Compound cantharis capsule com

关 键 词：胃癌 SOX化疗 复方斑蝥胶囊 Ras同源基因家族成员A/Rho激酶 

分 类 号：R73[医药卫生—肿瘤]